ArticleMedical oncology (Northwood, London, England)2022

A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen.

Farshid Dayyani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.